Antiretroviral Combinations

DRUG3 trials

Sponsors

National Institute of Cancerología, Chang Gung Memorial Hospital, Gilead Sciences

Conditions

HIV-1-InfectionHIV-1-infectionHuman Immunodeficiency VirusImmune Reconstitution SyndromeKaposi SarcomaNon-Adherence, Medication

Phase 2

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

CompletedNCT03296553

National Institute of CancerologíaHuman Immunodeficiency Virus, Immune Reconstitution Syndrome, Kaposi Sarcoma

Start: 2015-10-01End: 2019-08-26Updated: 2022-01-27

Phase 3

Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

Active, not recruitingNCT06507059

Chang Gung Memorial HospitalHIV-1-infection, Non-Adherence, Medication

Start: 2024-07-19End: 2027-02-28Target: 40Updated: 2026-10-26

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Active, not recruitingNCT06630299

Gilead SciencesHIV-1-Infection

Start: 2024-10-08End: 2030-08-01Target: 600Updated: 2026-05-29